WINTON GROUP Ltd Has $862,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

WINTON GROUP Ltd raised its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,772 shares of the company’s stock after buying an additional 2,111 shares during the quarter. WINTON GROUP Ltd’s holdings in Axsome Therapeutics were worth $862,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. US Bancorp DE grew its position in shares of Axsome Therapeutics by 3.5% during the 1st quarter. US Bancorp DE now owns 9,374 shares of the company’s stock worth $531,000 after buying an additional 313 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Axsome Therapeutics by 3.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,497 shares of the company’s stock worth $651,000 after buying an additional 340 shares during the period. American Century Companies Inc. grew its position in shares of Axsome Therapeutics by 0.4% during the 2nd quarter. American Century Companies Inc. now owns 129,303 shares of the company’s stock worth $8,723,000 after buying an additional 492 shares during the period. The PNC Financial Services Group Inc. grew its position in shares of Axsome Therapeutics by 2.4% during the 1st quarter. The PNC Financial Services Group Inc. now owns 21,228 shares of the company’s stock worth $1,201,000 after buying an additional 495 shares during the period. Finally, UBS Group AG grew its position in shares of Axsome Therapeutics by 5.9% during the 1st quarter. UBS Group AG now owns 9,444 shares of the company’s stock worth $535,000 after buying an additional 530 shares during the period. Institutional investors own 59.00% of the company’s stock.

Shares of Axsome Therapeutics stock opened at $28.53 on Friday. Axsome Therapeutics, Inc. has a 12-month low of $19.38 and a 12-month high of $87.24. The stock has a market cap of $1.08 billion, a P/E ratio of -9.42 and a beta of 2.41. The company has a quick ratio of 6.20, a current ratio of 6.20 and a debt-to-equity ratio of 0.68. The business’s 50 day moving average is $38.13 and its 200-day moving average is $53.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Sunday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.02. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -3.62 EPS for the current year.

AXSM has been the subject of several research analyst reports. William Blair reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, August 27th. Mizuho reiterated a “buy” rating and issued a $55.00 price objective on shares of Axsome Therapeutics in a research report on Monday, August 23rd. Berenberg Bank initiated coverage on Axsome Therapeutics in a research report on Thursday, June 10th. They issued a “buy” rating and a $112.00 price objective for the company.
SVB Leerink decreased their price objective on Axsome Therapeutics from $115.00 to $75.00 and set an “outperform” rating for the company in a research report on Tuesday, August 10th. Finally, BTIG Research decreased their price objective on Axsome Therapeutics from $123.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, August 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $99.67.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Featured Story: Correction

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.